You are forgetting a few little things. Can LL be statistically proven effective for severe to critical patients? We were told so and hope so, but we’re told that on M2M and it fell flat. Also, mgt has not yet proven they can properly submit paperwork to navigate the bureaucratic FDA to get approvals. A long way to go to see any revenue. If CYDY is successful, and it is a big if, there should be asymmetrical returns from current prices. Make no mistake, this is still a highly speculative play with dubious management.